^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Starasid (cytarabine ocfosfate)
i
Other names: YNK01
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nippon Kayaku
Drug class:
DNA synthesis inhibitor
Related drugs:
4d
RG1121403: Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (clinicaltrials.gov)
P1, N=20, Suspended, University of Washington | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • cytarabine • mitoxantrone • cladribine • Starasid (cytarabine ocfosfate)
10d
P30CA036727: Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (clinicaltrials.gov)
P2, N=75, Completed, University of Nebraska | Active, not recruiting --> Completed | Trial primary completion date: Oct 2024 --> Mar 2024
Trial completion • Trial primary completion date
|
Venclexta (venetoclax) • azacitidine • Rydapt (midostaurin) • decitabine • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride • Daurismo (glasdegib) • Starasid (cytarabine ocfosfate)
12d
AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov)
P3, N=5949, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Oct 2025
Trial completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6)
|
MLL rearrangement • MLL rearrangement
|
dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
12d
AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov)
P3, N=847, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025
Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD22 (CD22 Molecule) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • MPO (Myeloperoxidase)
|
CD22 expression
|
cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
18d
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025
Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3) • RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
|
FLT3 mutation • FLT3 wild-type
|
cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
21d
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia (clinicaltrials.gov)
P1/2, N=37, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2024 | Trial primary completion date: Dec 2026 --> Oct 2024
Trial completion • Trial completion date • Trial primary completion date
|
cytarabine • cladribine • uproleselan sodium (APL-106) • Starasid (cytarabine ocfosfate)
26d
AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
P2, N=300, Suspended, National Cancer Institute (NCI) | N=550 --> 300
Enrollment change • Combination therapy • Checkpoint inhibition
|
CD19 (CD19 Molecule)
|
CD19 expression
|
Opdivo (nivolumab) • cytarabine • Blincyto (blinatumomab) • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Hemady (dexamethasone tablets) • ABP 206 (nivolumab biosimilar) • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) • Starasid (cytarabine ocfosfate) • dexamethasone injection
27d
NCI-2021-02246: Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients (clinicaltrials.gov)
P1/2, N=55, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> Oct 2025
Trial completion date • Trial primary completion date • Combination therapy • Tumor mutational burden
|
BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax) • cytarabine • daunorubicin • Inqovi (decitabine/cedazuridine) • Starasid (cytarabine ocfosfate)
27d
NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=24, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | Trial completion date: Aug 2025 --> Feb 2026 | Trial primary completion date: Aug 2025 --> Feb 2026
Enrollment open • Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • Starasid (cytarabine ocfosfate)
1m
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)
P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2028 | Initiation date: Oct 2024 --> Jan 2025 | Trial primary completion date: Dec 2027 --> Dec 2028
Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
|
MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
|
BCL2 expression
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone
2ms
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
P3; Initiation date: Jul 2024 --> Feb 2025
Trial initiation date
|
ABL1 (ABL proto-oncogene 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD19 (CD19 Molecule) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF1R (Colony stimulating factor 1 receptor)
|
CD19 expression
|
TruSight RNA Pan-Cancer Panel
|
dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
2ms
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov)
P1, N=36, Recruiting, Children's Oncology Group | Trial completion date: Apr 2026 --> Jun 2026 | Trial primary completion date: Apr 2026 --> Jun 2026
Trial completion date • Trial primary completion date • Combination therapy
|
cytarabine • methotrexate • leucovorin calcium • fludarabine IV • Rytelo (imetelstat) • Starasid (cytarabine ocfosfate)
2ms
NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov)
P1, N=22, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date • Combination therapy
|
SELL (Selectin L)
|
cytarabine • leucovorin calcium • fludarabine IV • uproleselan sodium (APL-106) • Starasid (cytarabine ocfosfate)
2ms
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
P2, N=270, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
cytarabine • decitabine • Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
3ms
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2026
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • Starasid (cytarabine ocfosfate)
3ms
NCI-2019-08626: BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
P2, N=50, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
Trial completion date • Trial primary completion date • Combination therapy • Tumor mutational burden • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD47 (CD47 Molecule) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3)
|
Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)
4ms
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov)
P1, N=36, Recruiting, Children's Oncology Group | Initiation date: Jul 2024 --> Mar 2025
Trial initiation date • Combination therapy
|
cytarabine • methotrexate • leucovorin calcium • fludarabine IV • Rytelo (imetelstat) • Starasid (cytarabine ocfosfate)
4ms
NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov)
P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
SELL (Selectin L)
|
cytarabine • leucovorin calcium • fludarabine IV • uproleselan sodium (APL-106) • Starasid (cytarabine ocfosfate)
4ms
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
P2, N=153, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
Enrollment open
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • RARA (Retinoic Acid Receptor Alpha) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • PML (Promyelocytic Leukemia) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)
4ms
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
P1/2, N=4, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 4
Enrollment closed • Enrollment change
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
4ms
NCI-2019-08626: BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
P2, N=50, Recruiting, National Cancer Institute (NCI) | N=124 --> 50
Enrollment change • Combination therapy • Tumor mutational burden • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD47 (CD47 Molecule) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3)
|
Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)
4ms
AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P3; Recruiting --> Active, not recruiting
Combination therapy • Enrollment closed • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IKZF1 (IKAROS Family Zinc Finger 1) • CSF1R (Colony stimulating factor 1 receptor)
|
TruSight RNA Pan-Cancer Panel
|
imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • dexrazoxane
4ms
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov)
P3, N=280, Active, not recruiting, Children's Oncology Group | Trial completion date: Jun 2024 --> Jul 2025
Trial completion date
|
GATA1 (GATA Binding Protein 1)
|
cytarabine • etoposide IV • daunorubicin • mitoxantrone • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
4ms
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov)
P1, N=36, Recruiting, Children's Oncology Group | Not yet recruiting --> Recruiting
Enrollment open
|
cytarabine • methotrexate • leucovorin calcium • fludarabine IV • Rytelo (imetelstat) • Starasid (cytarabine ocfosfate)
4ms
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML (clinicaltrials.gov)
P2, N=40, Not yet recruiting, OHSU Knight Cancer Institute
New P2 trial
|
Venclexta (venetoclax) • cytarabine • azacitidine • cladribine • Starasid (cytarabine ocfosfate)
4ms
AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P3, N=218, Completed, Children's Oncology Group | Active, not recruiting --> Completed
Trial completion
|
cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • lestaurtinib (CEP-701) • mercaptopurine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
5ms
NCI-2019-01726: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=18, Recruiting, Uma Borate | Suspended --> Recruiting
Enrollment open • Combination therapy
|
FLT3 (Fms-related tyrosine kinase 3) • CD33 (CD33 Molecule)
|
cytarabine • Rydapt (midostaurin) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)
5ms
NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=24, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • Starasid (cytarabine ocfosfate)
6ms
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement (clinicaltrials.gov)
P1/2, N=6, Terminated, National Cancer Institute (NCI) | Phase classification: P1b/2 --> P1/2
Phase classification • Combination therapy
|
KMT2A (Lysine Methyltransferase 2A)
|
cytarabine • daunorubicin • pinometostat (EPZ-5676) • Starasid (cytarabine ocfosfate)
6ms
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=48, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Combination therapy
|
RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia) • CD4 (CD4 Molecule)
|
cytarabine • etoposide IV • mitoxantrone • peposertib (M3814) • Starasid (cytarabine ocfosfate)
6ms
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Combination therapy
|
cytarabine • navtemadlin (KRT-232) • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)
6ms
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1/2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • nelarabine • Starasid (cytarabine ocfosfate)
6ms
AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=80, Recruiting, Children's Oncology Group | Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
Trial completion date • Trial primary completion date
|
KMT2A (Lysine Methyltransferase 2A) • CD22 (CD22 Molecule)
|
cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate)
6ms
NCI-2019-01726: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=18, Suspended, Uma Borate | Recruiting --> Suspended
Trial suspension
|
FLT3 (Fms-related tyrosine kinase 3) • CD33 (CD33 Molecule)
|
CD33 positive • CD33 expression
|
cytarabine • Rydapt (midostaurin) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)
6ms
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
P2, N=268, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Mar 2027 | Trial primary completion date: Sep 2024 --> Mar 2027
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • azacitidine • Vyxeos (cytarabine/daunorubicin liposomal formulation) • Starasid (cytarabine ocfosfate)
6ms
NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=80, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
Enrollment open
|
Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • mercaptopurine • Starasid (cytarabine ocfosfate)
6ms
MyeloMATCH MSRP: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study (clinicaltrials.gov)
P2, N=750, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: May 2032 --> May 2029 | Trial primary completion date: May 2032 --> May 2029
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • Vyxeos (cytarabine/daunorubicin liposomal formulation) • Starasid (cytarabine ocfosfate)
6ms
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P3, N=302, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
Trial completion date • Trial primary completion date • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • TNFA (Tumor Necrosis Factor-Alpha) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • CD79A (CD79a Molecule) • GSTT1 (Glutathione S-transferase theta 1)
|
BCL2 expression • MYC expression • MYC translocation • CD79A mutation • CD79A mutation + CD79B mutation
|
Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)
7ms
NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=80, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
|
Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • mercaptopurine • Starasid (cytarabine ocfosfate)
7ms
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov)
P2, N=0, Withdrawn, National Cancer Institute (NCI) | N=154 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • navitoclax (ABT 263) • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
7ms
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=40, Completed, Wake Forest University Health Sciences | Unknown status --> Completed | Phase classification: P2 --> P1
Trial completion • Phase classification
|
cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)
7ms
VITAL: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (clinicaltrials.gov)
P2, N=42, Active, not recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Apr 2024 --> Sep 2024
Trial completion date • Combination therapy • Tumor mutational burden
|
SRC (SRC Proto-Oncogene)
|
cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)
Share via
